Fig. 1: The flow chart of this study. | Nature Communications

Fig. 1: The flow chart of this study.

From: Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial

Fig. 1

A Schematic overview of the therapeutic regimen. The illustration was prepared by Figdraw. B Clinical trial profile. ORR Overall Response Rate; PFS Progression-Free Survival; OS Overall Survival; DCR Disease Control Rate; GAC Gastric Adenocarcinoma; ESCC Esophageal Squamous Cell Carcinoma; AEs Adverse Events.

Back to article page